ClinicalTrials.gg
Status unknownNCT05128409Updated Apr 12, 2023

Phase I of XKH001Injection in Healthy Adults

A Phase 1 interventional study of XKH001 Injection and XKH001Placebo Injection in Healthy Adults, sponsored by Beijing Kanova Biopharmaceutical Co., LTD. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by Beijing Kanova Biopharmaceutical Co., LTD · Phase 1, Interventional, and Health services research

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

XKH001is a recombinant humanized monoclonal IgG1 antibody for subcutaneous injection. XKH001 specifically blocks interleukin-25 from binding to its receptors.

To evaluate the safety, tolerability, pharmacokinetics (PK) of single ascending doses of XKH001 injection following subcutaneous administration

Read the detailed description

This is a randomized, double-blind, placebo-controlled, phase 1 single ascending dose study to evaluate the safety, tolerability and pharmacokinetic characteristics of XKH001 in approximately 35 adult healthy volunteers.

The study will consist of a Screening Period (up to 21 days), an in-house Treatment Period, and a follow-up period.

Eligible subjects who signed the informed consent form (ICF) will be sequentially enrolled into one of the 5 dose cohorts: 0.5, 1.67, 3.34, 5.0 and 10.0 mg/kg. Three subjects will be enrolled in 0.5 mg/kg cohort (Cohort 1). All subjects in Cohort 1 will receive open-label XKH001. One sentinel participant will be dosed 48 hours prior to dosing the remainders of cohort 1. Eight subjects will be enrolled in the remaining dose cohorts (Cohort 2-5) and randomized to XKH001 or placebo after baseline evaluations are completed. Subjects will be admitted to the clinical research center the day before the administration of study drug (Day -1) For the study treatment of Cohort 2-5, the Investigator and other clinical center staff will be blinded. Any off-site staff who are unblinded will have no contact with the study participants. Two sentinel participants (randomized in a 1:1 ratio) will be dosed 48 hours prior to dosing the remainders of Cohort 2-5 (n=6, randomized in a 5:1 ratio). Subjects will be given a single dose of XKH001 or placebo (Cohort 2-5) on Day 1. After dosing, all subjects will be followed as inpatients through day 4. After discharge, all subjects will be followed for safety for 8 weeks and required to return to the clinical center for safety visits at the time points specified in Table 2.

A safety monitoring committee (SMC) will evaluate all available safety, and tolerability data within the first 21 days after the administration of the study drug. Escalation to the next higher dose level will stop if any of the stopping criteria defined in Section 7.1.2 is met. All subjects will have cleared the 21-day observation period at any given dose level before subjects are allowed to enroll at the next higher dose level. The dose level may be modified based on the emerging safety and PK data from this study via submission of a protocol amendment.

02

Conditions studied

  • Healthy Adults
03

In context

Lead sponsor

Beijing Kanova Biopharmaceutical Co., LTD is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide signed and dated prior to any study-related procedures and willing and able to comply with all study procedures.
  2. Healthy male and female subjects, 18-65 years of age (inclusive).
  3. (BMI) between 18 and 32.0 kg/m2.
  4. Generally, in good health, with no history of chronic or serious cardiovascular, hepatic, renal, respiratory, blood and lymphatic system, endocrine, immune, mental, neurological, psychiatric, gastrointestinal and allergic diseases.
  5. Vital signs, physical examination, clinical laboratory tests (CBC with differential, urinalysis, blood biochemistry, coagulation, pregnancy test (females), urine drug test and lipid panel , etc.), and 12-lead should be within normal reference range or abnormal not at screening and Admission (Day -1). For eligibility purposes, abnormal laboratory or vital signs results may be repeated once if abnormal result is observed at the initial reading. Moreover, Blood pressure must be within 90/50-140/90 mm/Hg. Respiratory rate must be within 12-18/minutes. Pulse must be within 60- 100/minute and the oral temperature must be \< 99.0 oF.
  6. No prescription or non-prescription drug within 14 days prior to the study drug administration and throughout the study.
  7. Women of non- defined as being surgically sterile (bilateral oophorectomy and hysterectomy) or menopause confirmed by FSH and Estradiol levels in accordance with local laboratory reference ranges.
  8. Women of childbearing potential who are not pregnant or breast-feeding must consent to use acceptable (Section 5.3) during the study and for an additional 30 days after the administration of study drug.
  9. Men with a partner of childbearing potential must consent to use acceptable contraception (Section 5.3) during the study and for an additional 90 days after the administration of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding woman.
  2. Within 5 years prior to the study, subjects with history of cardiovascular,respiratory, kidney, liver, metabolism, endocrine, gastrointestinal, blood, nerve, skin and mental illness, cancer or other major disease that in the judgement of the Investigator might put the subject at risk on this study.
  3. History of disease.
  4. Known history or family history of hereditary immunodeficiency; History of recurrent infection suggestive of immune deficiency.
  5. Positive test at screening for antibody (HIV1/HIV2), antibody or virus surface antigen (HBsAg) or hepatitis B core antibody (HBcAb), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing.
  6. Significant infections requiring hospitalization or intravenous antibiotics or as judged by the investigator within 3 months prior to dosing. Symptomatic viral, bacterial (including upper respiratory infection), or fungal (including cutaneous) infection within 1 week prior to dosing.
  7. Received live or attenuated vaccines within 6 weeks prior to dosing, or plan to be vaccinated with live or attenuated vaccines during the study or within 6 weeks after dosing.
  8. Received any experimental drugs or devices or have participated in a clinical study within 60 days prior to admission.
  9. Allergy to study drug or components of its formulation or history of a Grade 3-4 allergic reaction to treatment with another protein product.
  10. Abuse on alcohol, cannabis- derived products or other drugs.
  11. Positive urine drug test (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, cotinine and opiates) at screening and admission.
  12. Smoking or use of other nicotine-containing products (snuff, chewing tobacco, cigars, pipes or nicotinereplacement products such as nicotine chewing gum and nicotine plasters) within 3 months prior to admission, or negative cotinine test at screening period and Day -1,or during the trial.
  13. Donated or lost ≥ 450 mL of blood or received blood transfusion or blood products within 8 weeks prior to admission or donated ≥200 mL of blood (blood components) or had blood loss (≥300 mL) within 1 month prior to admission.
  14. Poor venous access or inability to tolerate venipuncture.
  15. Any condition that the investigator or primary physician believes may not be appropriate for participating the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (estimated)

Study arms

  • Active comparator
    XKH001 Injection

    XKH001 Injection,hypodermic injection,single dose,5 dose cohorts: 0.5 mg/kg, 1.67 mg/kg, 3.34 mg/kg, 5.0 mg/kg and 10.0 mg/kg.

    Drug: XKH001 Injection

  • Placebo comparator
    XKH001 Placebo Injection

    XKH001 Placebo Injection,hypodermic injection,single dose,4 dose cohorts: 1.67 mg/kg, 3.34 mg/kg, 5.0 mg/kg and 10.0 mg/kg.

    Drug: XKH001Placebo Injection

Interventions

  • 0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants

    Also known as: XKH001

  • DrugXKH001Placebo Injection

    1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants

    Also known as: XKH001Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Incidence of adverse events (AEs)

    Time frame: from admission to discharge, up to 8 weeks

  2. Incidence of serious adverse events (SAEs)

    Incidence of serious adverse events (SAEs)

    Time frame: from admission to discharge, up to 8 weeks

  3. AEs leading to termination of dose escalation

    AEs leading to termination of dose escalation

    Time frame: from admission to discharge, up to 8 weeks

  4. Reported values and changes from baseline in clinical laboratory investigations (hematology)

    Hematology test will include hematocrit, hemoglobin, red blood cell count, platelet count, white blood cell and neutrophil count, lymphocytes, monocytes, eosinophils, platelet and basophils.

    Time frame: from admission to discharge, up to 8 weeks

  5. Reported values and changes from baseline in clinical laboratory investigations (serum chemistry)

    Chemistry including sodium, potassium, chloride, creatinine, urea, blood glucose (baseline should check fasting blood glucose), serum albumin, calcium, magnesium, AST, ALT, ALP, LDH , total bilirubin, troponin, lipase and amylase will be tested.

    Time frame: from admission to discharge, up to 8 weeks

  6. Reported values and changes from baseline in clinical laboratory investigations ( urinalysis)

    A Urinalysis testing for color/appearance, pH, specific gravity, glucose, protein, ketones, blood and bilirubin . Microscopic analysis (for casts, crystals, epithelial cells, bacteria, RBCs, and WBCs) should be performed if any abnormalities are detected. Urine cotinine test Urine drug tests include cocaine, methamphetamines, amphetamines, barbiturates, opiates, benzodiazepines, cotinine and cannabinoids. Women must have negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test at screening and urine pregnancy test prior to administration of study drug on Day -1.

    Time frame: from admission to discharge, up to 8 weeks

  7. Reported values and changes from baseline in clinical laboratory investigations ( coagulation)

    International normalized ratio (INR) or Prothrombin time (PT) and partial thromboplastin time (PTT)

    Time frame: from admission to discharge, up to 8 weeks

  8. vital signs (respiratory rate)

    respiratory rate

    Time frame: from admission to discharge, up to 8 weeks

  9. vital signs (body temperature)

    body temperature

    Time frame: from admission to discharge, up to 8 weeks

  10. vital signs (supine blood pressure)

    supine blood pressure

    Time frame: from admission to discharge, up to 8 weeks

  11. vital signs (pulse)

    pulse

    Time frame: from admission to discharge, up to 8 weeks

  12. 12-lead electrocardiograms (ECGs)

    12-lead electrocardiograms (ECGs)

    Time frame: from admission to discharge, up to 8 weeks

  13. maximum serum concentration of XKH001

    maximum serum concentration of XKH001

    Time frame: from admission to discharge, up to 8 weeks

  14. time to reach maximum serum concentration of XKH001

    time to reach maximum serum concentration of XKH001

    Time frame: from admission to discharge, up to 8 weeks

  15. area under the serum concentration versus time curve from time zero to time t of XKH001

    area under the serum concentration versus time curve from time zero to time t of XKH001

    Time frame: from admission to discharge, up to 8 weeks

  16. systemic clearance of XKH001

    systemic clearance of XKH001

    Time frame: from admission to discharge, up to 8 weeks

  17. volume of distribution of XKH001

    volume of distribution of XKH001

    Time frame: from admission to discharge, up to 8 weeks

  18. terminal half-life of XKH001

    terminal half-life of XKH001

    Time frame: from admission to discharge, up to 8 weeks

Secondary outcomes

  1. To evaluate the immunogenicity of XKH001

    Incidence of anti-drug antibody (ADA) and neutralizing antibodies (NAbs)

    Time frame: from admission to discharge, up to 8 weeks

Other outcomes

  1. To explore pharmacodynamic biomarkers including serum IgE level

    serum IgE level

    Time frame: from admission to discharge, up to 8 weeks

  2. To explore pharmacodynamic biomarkers including blood eosinophil counts.

    blood eosinophil counts

    Time frame: from admission to discharge, up to 8 weeks

07

Study locations

1 site
  • The First Hospital of Jilin University Phase I Clinical Research Center
    Changchun, 130000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Oct 2024, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2021
First posted
Nov 22, 2021
StartActual
Mar 7, 2023
Primary completionEst.
Oct 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Apr 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05128409
Lead sponsor
Beijing Kanova Biopharmaceutical Co., LTD
Responsible party
Sponsor
First posted
Nov 22, 2021
Start date
Mar 7, 2023
Primary completion
Oct 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Apr 12, 2023

Study contacts

Yanhua Ding, MD
study chair · The First Hospital of Jilin University Phase I Clinical Research Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XKH001

Other studies from this sponsor

Beijing Kanova Biopharmaceutical Co., LTD

Start the discussion